Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys

This publication has 23 references indexed in Scilit:

• Immunogenicity of 2 Serogroup B Outer-Membrane Protein Meningococcal Vaccines
  JAMA, 1999
• Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine
  Vaccine, 1996
• Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine
  Vaccine, 1996
• Difficulties in Establishing a Serological Correlate of Protection After Immunization with Haemophilus Influenzae Conjugate Vaccines
  Biologicals, 1994
• The 5C Protein of Neisseria meningitidis Is Highly Immunogenic in Humans and Induces Bactericidal Antibodies
  The Journal of Infectious Diseases, 1993
• Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway
  The Lancet, 1991
• Antibodies to poly[(2----8)-alpha-N-acetylneuraminic acid] and poly[(2----9)-alpha-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coli K92 conjugates: potential vaccines for groups B and C meningococci and E. coli K1.
  Proceedings of the National Academy of Sciences, 1991
• Comparative evaluation of potential components for group B meningococcal vaccine by passive protection in the infant rat and in vitro bactericidal assay
  Vaccine, 1989
• Development of Antibodies to Meningococcal Protein and Lipopolysaccharide Serotype Antigens in Healthy Carriers
  Journal of Medical Microbiology, 1979
• HUMAN IMMUNITY TO THE MENINGOCOCCUS
  The Journal of Experimental Medicine, 1969